gpt-4-0613· OpenAI
Arena Human Preference 55K
Which anti-LAG3 candidate has the most promising clinical data?
- User
Which anti-LAG3 candidate has the most promising clinical data?
- Assistant
As an AI, I don't have real-time access to data, so I can't provide the current most promising anti-LAG3 candidate. However, as of my last update, Bristol-Myers Squibb's relatlimab (anti-LAG3) was showing promising results in clinical trials. Combined with nivolumab, it demonstrated increased progression-free survival rates in patients with metastatic or unresectable melanoma. Please consult the latest research or a healthcare professional for the most recent and accurate information.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.